Allogene Therapeutics (ALLO) Deferred Taxes (2018 - 2019)

Allogene Therapeutics (ALLO) reported Deferred Taxes of $33000.0 for Q3 2019, up 120.75% sequentially from -$159000.0 in Q2 2019.

Allogene Therapeutics (ALLO) Deferred Taxes (2018 - 2019) Analysis & Trends

Allogene Therapeutics (ALLO) has 2 years of Deferred Taxes data on file, last reported at $33000.0 in Q3 2019.

For the quarter ending Q3 2019, Deferred Taxes changed N/A year-over-year to $33000.0; the trailing twelve-month figure through Sep 2020 stood at $33000.0 (down 99.92% YoY), and the FY2018 full-year result was $41.9 million, changed N/A from the prior year.
Deferred Taxes rose to $33000.0 in Q3 2019, from -$159000.0 in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $41.9 million in Q4 2018 to a low of -$159000.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-65.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	96.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Allogene Therapeutics	437.33 Mn	437.33 Mn	-	-

Download Data